| Trademark Snap Shot Amendment & Mail Processing Stylesheet (Table presents the data on Amendment & Mail Processing Complete) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 90603915 | FILING DATE | 03/25/2021 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | N/A | INTL REG DATE | N/A |
| TM ATTORNEY | HSU, FONG |
L.O. ASSIGNED | O20-NOT FOUND |
PUB INFORMATION |
|||
| RUN DATE | 12/21/2021 | ||
| PUB DATE | N/A | ||
| STATUS | 661-RESPONSE AFTER NON-FINAL-ACTION-ENTERED | ||
| STATUS DATE | 12/20/2021 | ||
| LITERAL MARK ELEMENT | KRAZATI | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
| 1 (b) | YES | 1 (b) | YES | 1 (b) | NO |
| 44D | NO | 44D | NO | 44D | NO |
| 44E | NO | 44E | NO | 44E | NO |
| 66A | NO | 66A | NO | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | YES |
| LITERAL MARK ELEMENT | KRAZATI |
| MARK DRAWING CODE | 4-STANDARD CHARACTER MARK |
| COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | Mirati Therapeutics, Inc. |
| ADDRESS | 3545 Cray Court San Diego, CA 92121 |
| ENTITY | 03-CORPORATION |
| CITIZENSHIP | Delaware |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors |
| INTERNATIONAL CLASS | 042 |
| DESCRIPTION TEXT | research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
| INTERNATIONAL CLASS | 042 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 12/20/2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 013 |
| 12/20/2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 012 |
| 12/20/2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 011 |
| 11/09/2021 | ALIE | A | ASSIGNED TO LIE | 010 |
| 11/08/2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | 009 |
| 11/08/2021 | GNRT | F | NON-FINAL ACTION E-MAILED | 008 |
| 11/08/2021 | CNRT | R | NON-FINAL ACTION WRITTEN | 007 |
| 11/01/2021 | DOCK | D | ASSIGNED TO EXAMINER | 006 |
| 07/01/2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 005 |
| 06/30/2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 004 |
| 06/30/2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | 003 |
| 06/30/2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | 002 |
| 03/29/2021 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Eric R. Moran |
| CORRESPONDENCE ADDRESS | ERIC R. MORAN MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 SOUTH WACKER DRIVE 31ST FLOOR CHICAGO, IL 60606 |
| DOMESTIC REPRESENTATIVE | NONE |